Table 1

Patient characteristics, CTL infusions, and clinical status. WLE, wide local excision; LND, lymph node dissection; HD IL-2, high-dose IL-2; IFN, interferon-α; RT, radiation therapy; PD, progressive disease; SD, stable disease; CR, complete response; PR, partial response; MR, mixed response.

No.Age/sexMetastatic
disease at
study entry
Previous
therapy
Total cells infusedStatus on
day 70
Time
to next
therapy
Outcome
after CTL
or next
therapy
Duration
of response
(months)
Graft 1Graft 2
174/MLiver,
adrenal,
spleen,
lung,
skin
LND;
carboplatin,
paclitaxel,
sorafenib;
gp100 vaccine
4.0 × 108NoneDeath
on
day 51
Died
without
therapy
269/MLung,
skin
WLE; LND;
temozolomide;
melphalan limb perfusion
4.0 × 1084.0 × 108PDDay 103
ipilimumab
(10 mg/kg)
PR16
349/FLung,
adrenal
WLE; LND;
RT; HD IL-2
4.3 × 1084.3 × 108MRDay 146
ipilimumab
(10 mg/kg)
PR31+
468/MSkeletal muscle,
lung,
mediastinum,
cardiac
Small-bowel resection;
HD IL-2;
ipilimumab versus
gp100 versus both
3.8 × 1083.8 × 108SDDay 140
RAF265
SD3
566/MLymph nodesWLE; LND4.4 × 1092.5 × 109PRNo other therapyCR to CTL day 14025+
655/MLungWLE; LND;
pulmonary
nodule resection
1.8 × 1093.4 × 109SDDay 287
HD IL-2
Death due to line sepsis
770/FLung,
skin
WLE; LND;
adjuvant IFN
4.0 × 1094.0 × 109PDDay 335
ipilimumab
(3 mg/kg)
SD6
880/MLung,
mediastinum
LND; RT;
temozolomide
3.6 × 1093.6 × 109SDDay 372
ipilimumab
(3 mg/kg)
SD5
964/MLung,
skin
WLE; LND;
adjuvant IFN
4.4 × 1094.4 × 109PDDay 146
ipilimumab
(10 mg/kg) +
bevacizumab
PR13+